List of Excipients in Branded Drug VARIBAR THIN LIQUID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	VARIBAR THIN LIQUID	barium sulfate	32909-105	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	VARIBAR THIN LIQUID	barium sulfate	32909-105	CARBOXYMETHYLCELLULOSE SODIUM
E-Z-EM Canada Inc	VARIBAR THIN LIQUID	barium sulfate	32909-105	DIMETHICONE 1000

VARIBAR Thin Liquid Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

VARIBAR Thin Liquid is a 40% w/v barium sulfate oral suspension marketed by Bracco Diagnostics for videofluoroscopic evaluation of oropharyngeal swallowing. Its commercial value depends less on the novelty of barium sulfate than on excipient control of viscosity, sedimentation, redispersibility, palatability, dose uniformity, and compatibility with standardized swallowing protocols. The strongest opportunities are improved suspension systems, differentiated flavors and preservative platforms, hospital-ready packaging, and international or private-label products that preserve clinically validated rheology.

What is VARIBAR Thin Liquid?

VARIBAR Thin Liquid is a ready-to-use oral suspension containing barium sulfate at 40% weight/volume. It is used as a radiopaque contrast medium during modified barium swallow and other videofluoroscopic swallowing studies. The product is part of the VARIBAR product family, which includes preparations designed to represent different food and liquid consistencies.

The product is not a systemic pharmaceutical. Its performance is determined by physical properties at the point of administration:

• Radiopacity
• Apparent viscosity
• Sedimentation rate
• Redispersibility after storage
• Pourability and dose control
• Oral sensory characteristics
• Compatibility with swallowing-test protocols
• Stability after opening and during clinical use

The FDA-approved product is manufactured as a suspension rather than a solution because barium sulfate is practically insoluble in water. The formulation therefore requires a controlled excipient system to maintain a uniform concentration of suspended particles.

Core product profile

Attribute	VARIBAR Thin Liquid
Active ingredient	Barium sulfate
Strength	40% w/v
Dosage form	Oral suspension
Primary use	Videofluoroscopic evaluation of oropharyngeal swallowing
Commercial category	Diagnostic radiopaque contrast medium
Manufacturer	Bracco Diagnostics Inc.
FDA approval	2016 initial U.S. approval for the VARIBAR product family
Administration	Oral, under clinical supervision
Biosimilar relevance	None; product is not a biologic

The FDA labeling identifies sodium citrate, xanthan gum, potassium sorbate, methylparaben, sucralose, and natural and artificial flavoring components among the inactive ingredients for the VARIBAR formulation family. Exact excipient composition should be controlled against the current approved labeling and manufacturing specification because formulation changes can affect viscosity, preservative performance, and clinical comparability.[1]

Which excipients are used in VARIBAR Thin Liquid?

The excipient system has distinct technical roles. The primary formulation challenge is to maintain a high solids load while preserving a thin-liquid swallowing profile.

Excipient or excipient class	Likely formulation function	Commercial relevance
Xanthan gum	Suspending agent and rheology modifier	Controls sedimentation and flow behavior
Sodium citrate	Buffering and pH control	Supports stability and preservative performance
Potassium sorbate	Antimicrobial preservative	Controls microbial growth in an aqueous multidose suspension
Methylparaben	Antimicrobial preservative	Broadens preservation coverage
Sucralose	Sweetener	Improves oral acceptability without adding substantial sugar load
Natural and artificial flavors	Taste and odor masking	Supports patient acceptance during swallowing studies
Purified water	Continuous phase	Provides the liquid vehicle

How xanthan gum supports product performance

Xanthan gum is likely the key performance excipient. In a barium sulfate suspension, the polymer increases low-shear viscosity and limits rapid particle settling. It can also generate shear-thinning behavior, allowing the product to remain physically stable at rest while flowing during pouring and swallowing.

The concentration window is commercially sensitive. Too little xanthan gum can produce rapid settling, concentration gradients, and inaccurate dosing. Too much can move the preparation away from the intended thin-liquid consistency and interfere with the swallowing assessment. A replacement polymer would therefore need to match more than viscosity measured at a single shear rate.

Relevant development parameters include:

• Yield stress
• Viscosity across clinically relevant shear rates
• Sedimentation over the labeled shelf life
• Redispersibility after storage
• Particle-size distribution
• Pour rate
• Residual volume in the container
• Swallowing performance in standardized protocols

Why the preservative system matters

Potassium sorbate and methylparaben provide antimicrobial protection in an aqueous product that may be opened repeatedly during a study. The combination can reduce dependence on a single preservative mechanism, but it creates compatibility and regulatory considerations.

The preservation system must be evaluated against:

• Final pH
• Container-closure system
• Microbial challenge-test performance
• Preservative concentration over shelf life
• Adsorption to packaging
• Patient sensitivity and labeling requirements
• Regional restrictions on parabens

A preservative-free version could be commercially attractive for single-use packaging, but it would require a packaging strategy that prevents contamination without compromising usability in radiology and speech-pathology settings.

What formulation strategy protects the thin-liquid profile?

The central excipient strategy is to create a suspension that behaves as a thin liquid during administration while remaining stable during storage. That requires a controlled balance between polymer structure and particle loading.

Technical target

A commercially robust formulation should provide:

1. Uniform barium concentration from the first to the last dose.
2. Low settling during normal storage.
3. Easy redispersion without prolonged shaking.
4. Flow through common pouring and administration formats.
5. Consistent swallowing characteristics.
6. Acceptable taste and mouthfeel.
7. Stable radiopacity throughout shelf life.

The most defensible formulation-development approach is a design-of-experiments program covering polymer concentration, barium particle-size distribution, pH, ionic strength, preservative levels, and mixing energy.

Potential replacement excipients

Potential alternatives to xanthan gum include:

• Hydroxypropyl methylcellulose
• Carboxymethylcellulose
• Sodium alginate
• Gellan gum
• Microcrystalline cellulose and carboxymethylcellulose systems
• Poloxamer or other structured-liquid systems

Each alternative creates a different regulatory and technical profile. Cellulose derivatives may offer more predictable viscosity control, while gellan gum can provide suspension stability at low concentrations. Alginate may introduce ion sensitivity and a more noticeable mouthfeel. Microcrystalline cellulose systems can improve suspension stability but may produce a less natural thin-liquid flow profile.

The replacement must demonstrate pharmaceutical equivalence and clinically relevant rheological equivalence. A formulation that meets a simple viscosity specification may still alter swallow physiology or the fluoroscopic interpretation of bolus transit.

What commercial opportunities exist for VARIBAR Thin Liquid?

1. Premium excipient systems for suspension stability

Excipient suppliers can target ready-to-use radiopaque suspensions with low-settling, rapid-redispersion systems. The value proposition is operational rather than therapeutic:

• Less product waste
• Fewer failed or repeated studies
• More consistent bolus preparation
• Reduced staff handling
• Better dose uniformity
• Lower risk of using a nonstandard consistency

A supplier offering a prequalified polymer system with supporting rheology, microbial, and container-closure data could reduce development time for competing products.

2. Preservative-free single-use presentations

Single-dose cups, pouches, or unit-dose bottles could address contamination concerns and simplify workflow. The commercial tradeoff is higher packaging cost and more material per administered dose.

The strongest setting for this opportunity is a hospital or outpatient center that values:

• No shaking between multiple patients
• No open-container storage
• Lower cross-contamination risk
• Faster procedure preparation
• Easier inventory control

A preservative-free unit-dose product would need a validated barrier package and adequate suspension stability without relying on repeated manual agitation.

3. Packaging designed for controlled pouring

Packaging is part of the formulation strategy. Thin-liquid barium products can lose value if the container produces inconsistent pours, excessive residual volume, or poor visibility of remaining contents.

Potential differentiated formats include:

• Single-dose cups with wide openings
• Squeeze bottles with calibrated dispensing
• Low-residual-volume bottles
• Clearly labeled viscosity-specific containers
• Ready-to-use bags for controlled transfer
• Barcoded unit doses linked to procedure documentation

Packaging patents can sometimes provide more practical differentiation than a basic excipient substitution, particularly where the active ingredient is old and difficult to protect broadly.

4. Flavor and sensory differentiation

Flavoring is commercially relevant because swallowing-study patients may include children, older adults, and patients with neurological impairment. Poor taste can affect compliance and may complicate the clinical examination.

Potential opportunities include:

• Neutral or low-flavor formulations
• Citrus, vanilla, berry, or fruit profiles
• Pediatric flavor systems
• Sugar-free and low-intensity sweetener systems
• Reduced aftertaste
• Products optimized for patients with nausea or sensory hypersensitivity

Flavor changes require attention to preservative compatibility, pH, extractables and leachables, and regional labeling requirements. A flavor change can also affect the clinical acceptability of the product even when the physical formulation remains unchanged.

5. Global reformulation for excipient restrictions

Methylparaben and certain flavoring components may create regional commercialization issues. A global product strategy may require:

• Paraben-free variants
• Region-specific flavor systems
• Alternative preservatives
• Different sweetener systems
• Local excipient supplier qualification
• Separate packaging and labeling configurations

The opportunity is strongest in markets where the VARIBAR product family is unavailable or where hospitals use compounded barium preparations with less standardized consistency.

How does VARIBAR Thin Liquid compare with compounded barium products?

VARIBAR Thin Liquid competes with hospital-prepared barium suspensions, other commercial barium sulfate products, and thickened liquids prepared for swallowing studies.

Commercial factor	VARIBAR Thin Liquid	Compounded or manually prepared barium
Consistency control	Standardized commercial formulation	Operator-dependent
Excipient control	Defined and validated	May vary by site
Preparation time	Ready to use	Requires preparation
Sedimentation control	Formulated suspension system	Variable
Flavor	Controlled commercial profile	Often limited
Packaging	Manufacturer-controlled	Local containers
Regulatory documentation	FDA-approved labeling	Institutional procedures vary
Cost	Premium product pricing likely	Potentially lower direct cost
Clinical comparability	Designed for standardized use	May vary by recipe and operator

The commercial case for VARIBAR is strongest where consistency and workflow are more valuable than the lowest acquisition price. Competitors can attack on price, local availability, or customization. Bracco can defend the product through validated performance, standardized viscosity profiles, institutional contracts, and integrated product families.

What patents and exclusivity protect VARIBAR Thin Liquid?

VARIBAR Thin Liquid contains an established diagnostic active ingredient, barium sulfate. The likely protectable elements are the finished formulation, rheology profile, method of use in swallowing evaluation, packaging, and manufacturing process rather than the active molecule itself.

Patent and Orange Book assessment

Issue	Assessment
Active-ingredient patent	Not expected for barium sulfate
Formulation patents	Potentially relevant if claims cover suspension composition or rheology
Method-of-use patents	Potentially relevant to standardized swallowing examinations
Packaging patents	Potentially relevant to unit-dose or dispensing systems
Orange Book status	Must be evaluated against the current FDA Orange Book entry for the applicable NDA
Paragraph IV risk	Depends on any currently listed patents and the legal basis of a competing ANDA
Biosimilar risk	Not applicable
Small-molecule generic risk	Possible, subject to reference-product and formulation requirements

The product’s principal commercial barrier is likely formulation and clinical-performance replication rather than active-ingredient exclusivity. A generic applicant would need to match the reference product’s dosage form, strength, inactive ingredients where required, and performance characteristics. Differences in viscosity, sedimentation, flavor, or redispersibility could create development and regulatory obstacles.

The initial FDA approval date does not by itself establish the current patent-expiration date. Patent status should be determined from the current Orange Book, USPTO records, and litigation databases before making a launch or licensing decision.[2,3]

What generic entry risks exist for VARIBAR Thin Liquid?

Generic entry risk is moderate at the active-ingredient level and higher at the product-performance level.

Risk factors favoring generic entry

• Barium sulfate is an old, non-systemic active ingredient.
• The product is an oral suspension rather than a complex biologic.
• The active ingredient is widely used in diagnostic imaging.
• Excipient components are generally known pharmaceutical materials.
• A competing applicant could use an alternative 505(b)(2) or ANDA strategy depending on the reference-product and labeling requirements.

Barriers to rapid substitution

• High barium loading complicates suspension stability.
• Thin-liquid rheology must remain within a clinically useful range.
• Taste and mouthfeel affect patient cooperation.
• The product is used within a procedure, not simply dispensed for home administration.
• Clinical sites may require consistent performance across viscosity categories.
• A change in excipients could require substantial comparative data.
• Packaging and workflow can influence purchasing decisions.

A lower-priced product with inferior redispersibility could be clinically disruptive. Conversely, a competitor that matches the physical profile and offers unit-dose packaging could gain access through hospital tenders and group purchasing organizations.

Which licensing opportunities are most attractive?

The most attractive licensing targets are excipient and delivery technologies that improve measurable product attributes without changing the intended thin-liquid category.

High-value licensing targets

1. Low-shear suspension polymers with rapid redispersion.
2. Preservative-free unit-dose packaging.
3. Container systems with low residual volume.
4. Flavor platforms for pediatric and geriatric use.
5. Rheology analytics linked to swallowing-study consistency.
6. Manufacturing processes that reduce particle agglomeration.
7. Paraben-free global formulations.
8. Barcoded packaging and procedure-level inventory systems.

A licensing agreement could be structured around an exclusive field of use for radiopaque oral suspensions, with milestone payments tied to formulation selection, FDA supplement approval, commercial launch, and volume-based royalties.

How strong is the VARIBAR Thin Liquid commercial position?

The product has a defensible niche because it integrates an established contrast agent with a standardized swallowing-study workflow. Its competitive strength is highest in institutions that need reproducible thin-liquid consistency and low preparation burden.

Its main vulnerabilities are:

• Price competition from generic or hospital-prepared barium
• Institutional substitution with alternative commercial products
• Limited differentiation in the active ingredient
• Potential restrictions on parabens or flavor ingredients
• Procurement pressure from hospitals and group purchasing organizations
• Formulation replication by a technically capable competitor

The most durable strategy is to protect the complete use system: validated rheology, recognizable viscosity categories, convenient packaging, clinical workflow integration, and evidence that the formulation improves consistency or reduces procedure-related variability.

Key Takeaways

• VARIBAR Thin Liquid is a 40% w/v ready-to-use barium sulfate oral suspension for videofluoroscopic swallowing evaluation.
• Xanthan gum is the central rheology and suspension-control excipient.
• Sodium citrate, potassium sorbate, methylparaben, sucralose, and flavoring components support pH control, preservation, palatability, and product stability.
• The strongest formulation opportunity is a thin-liquid suspension with rapid redispersion and consistent swallowing behavior.
• Single-dose, preservative-free packaging is a credible commercial extension.
• Flavor, paraben-free, pediatric, and international variants can expand the addressable market.
• Generic risk is limited by formulation-performance requirements but not by active-ingredient novelty.
• Patent value, if available, is more likely to reside in formulation, method of use, packaging, or manufacturing than in barium sulfate itself.
• Licensing opportunities are strongest in excipient systems, unit-dose delivery, packaging, and rheology-control technologies.
• The current Orange Book and USPTO records should control any final exclusivity or patent-expiration assessment.

FAQs

Can xanthan gum be replaced in VARIBAR Thin Liquid?

Yes, but replacement requires matching suspension stability, flow behavior, redispersibility, oral sensory properties, and clinical swallowing performance. A simple viscosity match is insufficient.

Is VARIBAR Thin Liquid eligible for biosimilar competition?

No. VARIBAR Thin Liquid is a small-molecule diagnostic suspension containing barium sulfate. Any competition would arise through generic, 505(b)(2), or other drug-product pathways rather than the biosimilar pathway.

Could a preservative-free VARIBAR-type product be commercialized?

Yes. The most practical approach would be a validated single-dose container-closure system that eliminates repeated-use contamination risk and maintains suspension uniformity through administration.

What is the most valuable excipient innovation for a competing product?

A polymer and particle-engineering system that provides rapid redispersion, low sedimentation, and thin-liquid flow without changing the clinical swallowing profile would have the strongest technical value.

Does barium sulfate itself provide meaningful patent protection?

Generally, no. Barium sulfate is an established active ingredient. Commercial protection would more likely depend on formulation, use, packaging, manufacturing, regulatory exclusivity, and customer contracts.

References

1. U.S. Food and Drug Administration. (2016). VARIBAR Thin Liquid prescribing information. Bracco Diagnostics Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. United States Patent and Trademark Office. (n.d.). Patent Center and patent search records. https://patents.uspto.gov

4. U.S. Food and Drug Administration. (2016). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. USP Convention.